# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects

> **NCT03809039** · PHASE1 · TERMINATED · sponsor: **Tanabe Pharma America, Inc.** · enrollment: 52 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MT-6345
- **DRUG:** MT-6345 Placebo

## Key facts

- **NCT ID:** NCT03809039
- **Lead sponsor:** Tanabe Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-15
- **Primary completion:** 2019-07-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** Preclinical finding
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03809039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03809039, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03809039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*